Helixgate

Helixgate

Uncategorized

AstraZeneca’s breast cancer drug fails to earn backing of FDA advisory committee

Published

on

Members of the FDA’s Oncologic Drugs Advisory Committee questioned the design of AstraZeneca’s Phase 3 trial of camizestrant, which involved switching treatments at the point of mutation detection, as opposed to the current practice of changing regimens upon disease progression.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Acelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from China

Acelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from China

Published

on

Cue Biopharma announced a reboot Thursday afternoon, bringing in notable biotech executive Shao-Lee Lin as well as a new allergy asset developed in Taiwan and mainland China.

The Boston-based biotech has focused on developing T …​ ​Read More

Continue Reading

Uncategorized

Novartis unveils North Carolina API plant as final piece of $23B US expansion

Published

on

The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites.

Continue Reading

Uncategorized

Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.

Read More

Published

on

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.

Read More

Continue Reading
Advertisement

Trending